tm
Seeing Is Believing
tm
Seeing Is Believing
SABS is currently covered by 3 analysts with an average price target of $5.44. This is a potential upside of $3.83 (237.89%) from yesterday's end of day stock price of $1.61.
SAB Biotherapeutics's activity chart (see below) currently has 2 price targets and 23 ratings on display. The stock rating distribution of SABS is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 11.36% with an average time for these price targets to be met of 196 days.
Highest price target for SABS is $12, Lowest price target is $6, average price target is $6.
Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 29-Jan-2025. First documented stock forecast 05-Nov-2021.
Currently out of the existing stock ratings of SABS, 20 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
1 months 13 days ago
(29-Jan-2025)
1/4 (25%)
$-1.5 (-33.33%)
49
Buy
$6
$4.38 (270.37%)
$6
1 months 13 days ago
(29-Jan-2025)
1/11 (9.09%)
$3.77 (169.06%)
539
Buy
$12
$10.38 (640.74%)
$12
6 months 2 days ago
(12-Sep-2024)
0/2 (0%)
$9.23 (333.21%)
What is SABS (SAB Biotherapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on SABS (SAB Biotherapeutics) with a proven track record?
Which analyst has the current lower performing score on SABS (SAB Biotherapeutics) with a proven track record?
Which analyst has the most public recommendations on SABS (SAB Biotherapeutics)?
Which analyst is the currently most bullish on SABS (SAB Biotherapeutics)?
Which analyst is the currently most reserved on SABS (SAB Biotherapeutics)?
